vs
HALOZYME THERAPEUTICS, INC.（HALO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是REPLIGEN CORP的2.3倍（$451.8M vs $197.9M）。REPLIGEN CORP净利率更高（6.7% vs -31.3%，领先38.1%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs 13.6%）。HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $17.6M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs 14.4%）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
HALO vs RGEN — 直观对比
营收规模更大
HALO
是对方的2.3倍
$197.9M
营收增速更快
HALO
高出37.9%
13.6%
净利率更高
RGEN
高出38.1%
-31.3%
自由现金流更多
HALO
多$200.1M
$17.6M
两年增速更快
HALO
近两年复合增速
14.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $451.8M | $197.9M |
| 净利润 | $-141.6M | $13.3M |
| 毛利率 | 82.6% | 52.5% |
| 营业利润率 | -20.6% | 9.0% |
| 净利率 | -31.3% | 6.7% |
| 营收同比 | 51.6% | 13.6% |
| 净利润同比 | -203.3% | 143.9% |
| 每股收益（稀释后） | $-1.13 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HALORGEN
| Q4 25 | $451.8M | $197.9M | ||
| Q3 25 | $354.3M | $188.8M | ||
| Q2 25 | $325.7M | $182.4M | ||
| Q1 25 | $264.9M | $169.2M | ||
| Q4 24 | $298.0M | $174.1M | ||
| Q3 24 | $290.1M | $154.9M | ||
| Q2 24 | $231.4M | $154.1M | ||
| Q1 24 | $195.9M | $151.3M |
净利润HALORGEN
| Q4 25 | $-141.6M | $13.3M | ||
| Q3 25 | $175.2M | $14.9M | ||
| Q2 25 | $165.2M | $14.9M | ||
| Q1 25 | $118.1M | $5.8M | ||
| Q4 24 | $137.0M | $-30.3M | ||
| Q3 24 | $137.0M | $-654.0K | ||
| Q2 24 | $93.2M | $3.3M | ||
| Q1 24 | $76.8M | $2.1M |
毛利率HALORGEN
| Q4 25 | 82.6% | 52.5% | ||
| Q3 25 | 84.4% | 53.2% | ||
| Q2 25 | 85.8% | 50.0% | ||
| Q1 25 | 81.7% | 53.6% | ||
| Q4 24 | 85.9% | 26.1% | ||
| Q3 24 | 83.0% | 50.0% | ||
| Q2 24 | 82.9% | 49.8% | ||
| Q1 24 | 85.5% | 49.5% |
营业利润率HALORGEN
| Q4 25 | -20.6% | 9.0% | ||
| Q3 25 | 61.5% | 8.9% | ||
| Q2 25 | 62.2% | 7.6% | ||
| Q1 25 | 53.4% | 3.9% | ||
| Q4 24 | 58.9% | -17.7% | ||
| Q3 24 | 56.3% | -5.1% | ||
| Q2 24 | 50.7% | 1.0% | ||
| Q1 24 | 48.8% | 1.3% |
净利率HALORGEN
| Q4 25 | -31.3% | 6.7% | ||
| Q3 25 | 49.5% | 7.9% | ||
| Q2 25 | 50.7% | 8.2% | ||
| Q1 25 | 44.6% | 3.4% | ||
| Q4 24 | 46.0% | -17.4% | ||
| Q3 24 | 47.2% | -0.4% | ||
| Q2 24 | 40.3% | 2.2% | ||
| Q1 24 | 39.2% | 1.4% |
每股收益（稀释后）HALORGEN
| Q4 25 | $-1.13 | $0.24 | ||
| Q3 25 | $1.43 | $0.26 | ||
| Q2 25 | $1.33 | $0.26 | ||
| Q1 25 | $0.93 | $0.10 | ||
| Q4 24 | $1.06 | $-0.55 | ||
| Q3 24 | $1.05 | $-0.01 | ||
| Q2 24 | $0.72 | $0.06 | ||
| Q1 24 | $0.60 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.8M | $767.6M |
| 总债务越低越好 | $2.1B | $542.2M |
| 股东权益账面价值 | $48.8M | $2.1B |
| 总资产 | $2.5B | $2.9B |
| 负债/权益比越低杠杆越低 | 43.89× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资HALORGEN
| Q4 25 | $133.8M | $767.6M | ||
| Q3 25 | $419.7M | $748.7M | ||
| Q2 25 | $61.9M | $708.9M | ||
| Q1 25 | $176.3M | $697.2M | ||
| Q4 24 | $115.8M | $757.4M | ||
| Q3 24 | $154.3M | $784.0M | ||
| Q2 24 | $187.9M | $809.1M | ||
| Q1 24 | $164.6M | $780.6M |
总债务HALORGEN
| Q4 25 | $2.1B | $542.2M | ||
| Q3 25 | $1.5B | $537.9M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $525.6M | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益HALORGEN
| Q4 25 | $48.8M | $2.1B | ||
| Q3 25 | $503.9M | $2.1B | ||
| Q2 25 | $332.7M | $2.1B | ||
| Q1 25 | $482.3M | $2.0B | ||
| Q4 24 | $363.8M | $2.0B | ||
| Q3 24 | $452.7M | $2.0B | ||
| Q2 24 | $289.4M | $2.0B | ||
| Q1 24 | $177.8M | $2.0B |
总资产HALORGEN
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.2B | $2.9B | ||
| Q2 25 | $2.1B | $2.9B | ||
| Q1 25 | $2.2B | $2.9B | ||
| Q4 24 | $2.1B | $2.8B | ||
| Q3 24 | $2.1B | $2.8B | ||
| Q2 24 | $2.0B | $2.9B | ||
| Q1 24 | $1.8B | $2.8B |
负债/权益比HALORGEN
| Q4 25 | 43.89× | 0.26× | ||
| Q3 25 | 3.00× | 0.26× | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | 0.27× | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $219.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $217.6M | $17.6M |
| 自由现金流率自由现金流/营收 | 48.2% | 8.9% |
| 资本支出强度资本支出/营收 | 0.3% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $644.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流HALORGEN
| Q4 25 | $219.0M | $25.7M | ||
| Q3 25 | $178.6M | $48.1M | ||
| Q2 25 | $99.7M | $28.6M | ||
| Q1 25 | $154.2M | $15.0M | ||
| Q4 24 | $178.5M | $39.2M | ||
| Q3 24 | $115.4M | $49.3M | ||
| Q2 24 | $55.8M | $42.2M | ||
| Q1 24 | $129.4M | $44.7M |
自由现金流HALORGEN
| Q4 25 | $217.6M | $17.6M | ||
| Q3 25 | $175.6M | $43.4M | ||
| Q2 25 | $98.1M | $21.5M | ||
| Q1 25 | $153.3M | $11.4M | ||
| Q4 24 | $175.4M | $33.6M | ||
| Q3 24 | $113.9M | $42.3M | ||
| Q2 24 | $53.2M | $37.4M | ||
| Q1 24 | $125.9M | $36.4M |
自由现金流率HALORGEN
| Q4 25 | 48.2% | 8.9% | ||
| Q3 25 | 49.6% | 23.0% | ||
| Q2 25 | 30.1% | 11.8% | ||
| Q1 25 | 57.9% | 6.8% | ||
| Q4 24 | 58.9% | 19.3% | ||
| Q3 24 | 39.3% | 27.3% | ||
| Q2 24 | 23.0% | 24.3% | ||
| Q1 24 | 64.3% | 24.0% |
资本支出强度HALORGEN
| Q4 25 | 0.3% | 4.1% | ||
| Q3 25 | 0.9% | 2.5% | ||
| Q2 25 | 0.5% | 3.9% | ||
| Q1 25 | 0.4% | 2.1% | ||
| Q4 24 | 1.0% | 3.2% | ||
| Q3 24 | 0.5% | 4.5% | ||
| Q2 24 | 1.1% | 3.1% | ||
| Q1 24 | 1.8% | 5.5% |
现金转化率HALORGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 1.02× | 3.23× | ||
| Q2 25 | 0.60× | 1.92× | ||
| Q1 25 | 1.31× | 2.57× | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.60× | 12.70× | ||
| Q1 24 | 1.68× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
RGEN
暂无分部数据
